Warning: The NCBI web site requires JavaScript to function. more...
Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.
Stomrud E, Björkqvist M, Janciauskiene S, Minthon L, Hansson O.
Alzheimers Res Ther. 2010 Jun 24;2(3):20.
Related citations
Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
Biol Psychiatry. 2004 Nov 1;56(9):670-6.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L.
Lancet Neurol. 2006 Mar;5(3):228-34. Erratum in: Lancet Neurol. 2006 Apr;5(4):293.
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.
Dement Geriatr Cogn Disord. 2009;27(5):458-64. Epub 2009 May 7.
Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
J Alzheimers Dis. 2010;21(2):471-8.
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.
Arch Neurol. 1998 Jul;55(7):937-45.
Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
Bjerke M, Zetterberg H, Edman Å, Blennow K, Wallin A, Andreasson U.
J Alzheimers Dis. 2011;27(3):665-76.
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.
Arch Neurol. 2009 Mar;66(3):382-9.
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.
Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.
CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.
Neurosci Lett. 2008 Aug 1;440(2):145-9. Epub 2008 May 24.
Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.
Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.
Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. Epub 2008 Sep 19.
Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP.
Neurochem Int. 2006 Mar;48(4):286-95. Epub 2006 Jan 24.
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.
Acta Neurol Scand Suppl. 2003;179:47-51.
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
Arch Gen Psychiatry. 2012 Jan;69(1):98-106.
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.
Alzheimers Dement. 2008 Jan;4(1):38-48. Epub 2007 Dec 21. Review.
Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years.
Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E.
Neurobiol Aging. 2010 Feb;31(2):215-23. Epub .
CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.
Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P Sr, Soininen H.
Neurology. 1998 Jan;50(1):169-74.
CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM.
J Alzheimers Dis. 2009;16(3):601-7.
Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.
JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.
Neurobiol Aging. 2010 Aug;31(8):1340-54. Epub 2010 Jun 8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on